Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Cardiovasc Diabetol
; 22(1): 330, 2023 11 28.
Article
in En
| MEDLINE
| ID: mdl-38017482
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 2
/
Renal Insufficiency, Chronic
Limits:
Humans
Language:
En
Journal:
Cardiovasc Diabetol
Journal subject:
ANGIOLOGIA
/
CARDIOLOGIA
/
ENDOCRINOLOGIA
Year:
2023
Document type:
Article
Affiliation country: